

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Graham P. Allaway et al.

Serial No. : 09/888,938

Examiner: Bo Peng, Ph.D.

Filed : June 25, 2001

Group Art Unit: 1648

For : METHODS FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS

30 Rockefeller Plaza, 20th Flr.
New York, New York 10112
February 19, 2009

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following items, which are listed on the Substitute Form PTO-1449 attached hereto as **Exhibit A**. Items 1-2 are either U.S. Patents or U.S. Patent Application Publications. As permitted by 37 C.F.R. 1.98(a)(2)(ii), no copies of items 1-2 are included herewith. Copies of items 3-22 are attached hereto as **Exhibits 1-20**, respectively.

1. U.S. Patent Application Publication No. 2007-0274986 A1, published November 29, 2007 to W.C. Olson and Paul J. Maddon;
2. U.S. Patent Application Publication No. 2007-0231327 A1, published October 4, 2007 to W.C. Olson and Paul J. Maddon;
3. September 12, 2007 Final Office Action issued in connection with U.S. Serial No. 11/400,497 (**Exhibit 1**);
4. September 11, 2008 Office Action issued in connection with U.S. Serial No. 11/805,573 (**Exhibit 2**);
5. April 9, 2008 Office Action issued in connection with U.S. Serial No. 11/316,078 (**Exhibit 3**);

6. May 14, 2008 Office Action issued in connection with U.S. Serial No. 11/400,497 (**Exhibit 4**);
7. Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Or the Declaration issued July 25, 2008 in connection with PCT International Application No. PCT/US06/28565 (**Exhibit 5**);
8. Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, Or the Declaration issued August 15, 2008 in connection with PCT International Application No. PCT/US08/05564 (**Exhibit 6**);
9. May 15, 2008 Office Action issued in connection with U.S. Serial No. 11/581,945 (**Exhibit 7**);
10. September 16, 2008 Communication including a May 29, 2008 Extended European Search report in connection with European Patent Application No. 07014859.8 (**Exhibit 8**);
11. PCT International Application Publication No. WO 94/19017, published September 1, 1994 (**Exhibit 9**);
12. October 2, 2008 Communication Pursuant to Article 94(3) EPC and Result of Consultation issued in connection with European Patent Application No. 01970984.9 (**Exhibit 10**);
13. Office Action issued November 10, 2008 in connection with U.S. Serial No. 11/400,497 (**Exhibit 11**);
14. Office Action issued December 12, 2008 in connection with U.S. Serial No. 11/491,330 (**Exhibit 12**);
15. Final Office Action issued December 31, 2008 in connection with U.S. Serial No. 11/581,945 (**Exhibit 13**);
16. Final Office Action issued January 9, 2009 in connection with U.S. Serial No. 11/451,707 (**Exhibit 14**);
17. Decision to refuse European Patent Application issued November 26, 2007 by the European Patent Office in European Patent Application No. 97917856.3 (**Exhibit 15**);

18. April 7, 2008 Statement Setting Out Grounds Of Appeal (Article 108 EPC) filed by applicants in connection with European Application No. 97917856.3 (**Exhibit 16**);
19. Final Office Action issued January 27, 2009 in connection with U.S. Serial No. 11/520,556 (**Exhibit 17**);
20. Final Office Action issued January 27, 2009 in connection with U.S. Serial No. 11/259,540 (**Exhibit 18**);
21. Simmons, G. et al. (1996) "Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry," J. Virol. 70(12):8355-8360 (**Exhibit 19**); and
22. Valentin, A. et al. (1994) "Dual tropism for macrophages and lymphocytes is a common feature of primary human immunodeficiency virus type 1 and 2 isolates," J. Virol. 68(10):6684-6689 (**Exhibit 20**).

This Supplemental Information Disclosure Statement is being submitted under 37 C.F.R. 1.97(c)(2). Accordingly, applicants enclose herewith a check in the amount of \$180.00.


The Examiner is respectfully requested to make the listed items of record in the present application by initialing and returning a copy of the enclosed Substitute Form PTO 1449.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Applicants: Graham P. Allaway et al.
U.S. Serial No.: 09/888,938
Filed: June 25, 2001
Page 4

No fee, other than the enclosed \$180.00 Information Disclosure Statement fee, is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.


Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
Customer No. 079057
30 Rockefeller Plaza, 20th Flr.
New York, New York 10112
Tel. No. (212) 278-0400

I hereby certify that this correspondence is being deposited on this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment,
Commissioner for Patents,
P.O. Box 1450,
Alexandria, VA 22313-1450



John P. White
Reg. No. 28,678

2/19/09
Date

EXHIBIT A